Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890543 | 0.76 | CA12 (0.44) | ROCK1CA12CA1CA2CA9 | |
| SCHEMBL12561879 | 0.73 | UTS2R (0.55) | PRKCIAXLROCK1PTK2JAK2 | |
| SCHEMBL857193 | 0.73 | PKM (0.56) | PRKCIAXLROCK1PTK2JAK2 | |
| SCHEMBL1881471 | 0.72 | HTR1A (0.67) | — | |
| SCHEMBL4890538 | 0.72 | CA12 (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL5311905 | 0.72 | PTPN1 (0.58) | PRKCIAXLROCK1JAK2JAK1 | |
| SCHEMBL3093132 | 0.72 | PRKCI (0.55) | PRKCIAXLROCK1PTK2JAK2 | |
| SCHEMBL23070410 | 0.71 | CYP1A2 (0.70) | — | |
| SCHEMBL20508767 | 0.70 | NUDT1 (0.48) | PRKCIAXLROCK1PTK2JAK2 | |
| SCHEMBL15556761 | 0.70 | PRKCI (0.36) | PRKCIAXLPTK2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1539763-A4 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | PRKCI 757/4885AXL 103/4885ROCK1 208/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | PRKCI 754/4885AXL 82/4885ROCK1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.